Oncology. What changed.
New drugs and devices in oncology, newest first, each with its bottom line.
As of , Clintelo tracks 4 innovations in oncology: 2 drugs (Rasonque (daraxonrasib) and Lifyorli (relacorilant)) and 2 devices (Signatera CDx and Optune Pax). Each is written from the FDA's announcement or the developer's own release.
Drug IQ in Oncology
Search 2 in Drug IQ- Drug IQFDA approvalRasonque (daraxonrasib)Metastatic pancreatic adenocarcinoma · Revolution MedicinesAdults with previously treated metastatic pancreatic adenocarcinoma have an oral targeted option that extended median overall survival over standard chemotherapy in its pivotal trial.
- Drug IQFDA approvalLifyorli (relacorilant)Platinum-resistant ovarian cancer · Corcept TherapeuticsAdding relacorilant to nab-paclitaxel lengthened both progression-free and overall survival in previously treated platinum-resistant disease. Patients who need chronic or frequent glucocorticoids were excluded from the trial.
Device IQ in Oncology
Search 2 in Device IQ- Device IQApproved · PMASignatera CDxMuscle invasive bladder cancer, selection for adjuvant atezolizumab · NateraAfter cystectomy for muscle invasive bladder cancer, a positive Signatera CDx result identifies patients eligible for adjuvant atezolizumab. Patients who test negative should continue serial testing until a positive result or the end of the recommended 12-month testing window.
- Device IQApproved · PMAOptune PaxLocally advanced pancreatic cancer · NovocureAdults with locally advanced pancreatic cancer have a wearable device option; in the pivotal study, adding it to gemcitabine and nab-paclitaxel improved overall survival by approximately two months. The device is designed to be worn during normal daily activities, and patients are trained to operate it themselves.